SFRP1 reduction results in an increased sensitivity to TGF-β signaling

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Gauger, Kelly J ^a,b   Chenausky, Kerry L ^b   Murray, Molly E ^b   Schneider, Sallie S ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ZEB2; REGULATOR PROTEIN; RNA; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; LY 364947; LY-364947; MEMBRANE PROTEIN; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; REPRESSOR PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TELOMERASE; ZEB2 PROTEIN, HUMAN;

ARTICLE; BREAST EPITHELIUM; CELL CULTURE; CELL IMMORTALIZATION; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENOTYPE; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DOWN REGULATION; DRUG ANTAGONISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION;

ANIMALS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PYRAZOLES; PYRROLES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA;

EID: 79551681371     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-59     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
2. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8621-8623. 10.1073/pnas.1633291100, 166359, 12861075.
3. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & development 1995, 9:1831-1845.
4. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23:912-923. 10.1002/bies.1132, 11598958.
5. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of clinical investigation 2002, 109:1551-1559. 151012, 12070302.
6. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2006, 25:3408-3423. 10.1038/sj.onc.1208964, 16186809.
7. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8430-8435. 10.1073/pnas.0932636100, 166246, 12808151.
8. Polakis P. Wnt signaling and cancer. Genes & development 2000, 14:1837-1851.
9. Brown AM. Wnt signaling in breast cancer: have we come full circle?. Breast Cancer Res 2001, 3:351-355. 10.1186/bcr321, 138699, 11737884.
10. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. Journal of mammary gland biology and neoplasia 2004, 9:119-131. 10.1023/B:JOMG.0000037157.94207.33, 15300008.
11. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6770-6775. 10.1073/pnas.94.13.6770, 21233, 9192640.
12. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. The Journal of biological chemistry 1999, 274:16180-16187. 10.1074/jbc.274.23.16180, 10347172.
13. Zhou Z, Wang J, Han X, Zhou J, Linder S. Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. International journal of cancer 1998, 78:95-99.
14. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002, 196:145-153. 10.1002/path.1035, 11793365.
15. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International journal of oncology 2004, 25:641-649.
16. Gauger KJ, Hugh JM, Troester MA, Schneider SS. Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer cell international 2009, 9:11. 10.1186/1475-2867-9-11, 2687411, 19422694.
17. Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, et al. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. The Journal of biological chemistry 1999, 274:20489-20498. 10.1074/jbc.274.29.20489, 10400677.
18. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F, Berx G. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic acids research 2005, 33:6566-6578. 10.1093/nar/gki965, 1298926, 16314317.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159. 10.1016/0003-2697(87)90021-2, 2440339.
20. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of clinical investigation 2009, 119:2678-2690. 10.1172/JCI37815, 2735914, 19726885.
21. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proceedings of the Japan Academy 2009, 85:314-323.
22. Sandler MA, Zhang JN, Westerhausen DR, Billadello JJ. A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. The Journal of biological chemistry 1994, 269:21500-21504.
23. Ignotz RA, Heino J, Massague J. Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. The Journal of biological chemistry 1989, 264:389-392.
24. Giehl K, Imamichi Y, Menke A. Smad4-independent TGF-beta signaling in tumor cell migration. Cells, tissues, organs 2007, 185:123-130. 10.1159/000101313, 17587818.
25. Attisano L, Labbe E. TGFbeta and Wnt pathway cross-talk. Cancer metastasis reviews 2004, 23:53-61. 10.1023/A:1025811012690, 15000149.
26. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell research 2009, 19:71-88. 10.1038/cr.2008.302, 19002158.
27. Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer research 2007, 67:75-84. 10.1158/0008-5472.CAN-06-2559, 17210685.
28. Hussein SM, Duff EK, Sirard C. Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. The Journal of biological chemistry 2003, 278:48805-48814. 10.1074/jbc.M305472200, 14551209.
29. James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development (Cambridge, England) 2005, 132:1273-1282.
30. Gauger KJ, Rodriguez-Cortes A, Hartwich M, Schneider SS. Rhodiola Crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. Journal of Medicinal Plants Research 2010, 5.
31. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. Molecular definition of breast tumor heterogeneity. Cancer cell 2007, 11:259-273. 10.1016/j.ccr.2007.01.013, 17349583.
32. Baum O, Hlushchuk R, Forster A, Greiner R, Clezardin P, Zhao Y, Djonov V, Gruber G. Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. International journal of oncology 2007, 30:325-332.
33. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer research 2007, 67:3752-3758. 10.1158/0008-5472.CAN-06-3851, 17440088.
34. Sheldrake HM, Patterson LH. Function and antagonism of beta3 integrins in the development of cancer therapy. Current cancer drug targets 2009, 9:519-540. 10.2174/156800909788486713, 19519320.
35. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Current cancer drug targets 2009, 9:32-71. 10.2174/156800909787314002, 19200050.
36. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer treatment reviews 2008, 34:122-136. 10.1016/j.ctrv.2007.10.005, 18162327.
37. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature medicine 1998, 4:923-928. 10.1038/nm0898-923, 9701244.
38. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer research 2000, 60:5839-5847.
39. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006, 4:2710-2715. 10.1111/j.1538-7836.2006.02244.x, 17010152.
40. Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia (New York, NY 2005, 7:57-66.
41. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643. 10.1002/cncr.20946, 15742334.
42. Imamichi Y, Waidmann O, Hein R, Eleftheriou P, Giehl K, Menke A. TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem 2005, 386:225-236. 10.1515/BC.2005.028, 15843168.
43. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002, 32:153-159. 10.1038/ng950, 12185366.
44. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Molecular cell 2001, 7:1267-1278. 10.1016/S1097-2765(01)00260-X, 11430829.
45. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 2006, 25:4975-4985. 10.1038/sj.onc.1209511, 16568083.
46. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer research 2003, 63:2658-2664.